20042025

Research activity per year

Personal profile

Biography

Dr. Goode is a Senior Lecturer and head of the Cancer Bioinformatics and Tumour Evolution group in the Monash University Dept of Biochemistry & Molecular Biology  and the Monash Biomedicine Discovery Institute. 

His research applies bioinformatics, molecular evolution and population genetics to large cancer genomics data sets to study how tumours evolve and adapt. Areas of active interest include how changes in gene regulation and microenvironmental factors lead to phenotypic plasticity and therapy resistance in cancer cells. 

Dr Goode's group have  strong track records in prostate cancer and brain cancer, but have worked across a range of solid tumours. We take an evolutionary lens to cancer 'omics to study all stages of tumour evolution, through in-depth analysis of large genome, RNA sequencing and spatial profiling data sets from cancer patients and laboratory models of cancer. Increasingly, we incorporate machine learning and computational modeling to address questions of translational importance.

Dr Goode has published 59 peer-reviewed articles, with an H-index of 24 (Web of Science) and senior author publications in Genome Biology, PNAS and eLife, among others. He has held a Mid-Career Fellowship from the Victorian Cancer Agency (2018-2023) and a Peter Dohery Early Career Fellowship from the NHMRC (2013-2016). 

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Research area keywords

  • Cancer
  • Bioinformatics
  • Genomics
  • Transcriptomics
  • Evolution
  • Oncology
  • Drug Resistance
  • Prostate Cancer
  • Brain Cancer
  • Single Cell Genomics
  • Spatial Transcriptomics

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
  • Boosting conventional radiotherapy with microbeams to advance cancer treatment outcomes

    Martin, O. (Primary Chief Investigator (PCI)), Goode, D. (Associate Investigator (AI)), Djonov, V. (Chief Investigator (CI)), Tehei, M. (Chief Investigator (CI)), Kok, D. (Chief Investigator (CI)), Ryan, S. (Chief Investigator (CI)), Engels, E. (Chief Investigator (CI)), Anderson, R. (Associate Investigator (AI)), Lerch, M. (Associate Investigator (AI)), Hausermann, D. (Associate Investigator (AI)), Corde, S. (Associate Investigator (AI)), Klein, M. (Associate Investigator (AI)), MacManus, M. (Associate Investigator (AI)) & Park, S. (Associate Investigator (AI))

    3/02/2531/12/28

    Project: Research

  • Early Bipolar Androgen Therapy for Advanced Prostate Cancer

    Lawrence, M. (Primary Chief Investigator (PCI)), Selth, L. A. (Chief Investigator (CI)), Crumbaker, M. (Chief Investigator (CI)), Joshua, A. M. (Chief Investigator (CI)), Denmeade, S. (Chief Investigator (CI)), Taylor, R. (Associate Investigator (AI)), Ryan, A. (Associate Investigator (AI)), Lau, X. (Associate Investigator (AI)), Butler, L. M. (Associate Investigator (AI)), Goode, D. (Associate Investigator (AI)), Mills, I. G. (Associate Investigator (AI)) & Quezada Urban, R. (Associate Investigator (AI))

    1/01/2531/12/28

    Project: Research

  • “GLIMMER” - Glioma Liquid biopsy and Multiomic-Monitoring Enabled Research platform

    Whittle, J. R. (Primary Chief Investigator (PCI)), Jenkins, M. R. (Chief Investigator (CI)), Freytag, S. (Chief Investigator (CI)), Best, S. A. (Chief Investigator (CI)), Morokoff, A. (Chief Investigator (CI)), Goode, D. (Chief Investigator (CI)), Wong, S. Q. (Chief Investigator (CI)), Grimmond, S. (Chief Investigator (CI)), Fox, S. B. (Chief Investigator (CI)), Dawson, S.-J. (Chief Investigator (CI)), Gately, L. (Chief Investigator (CI)), Drummond, K. J. (Chief Investigator (CI)), Eisenstat, D. D. (Chief Investigator (CI)) & Palmer, L. M. (Chief Investigator (CI))

    1/01/2231/10/27

    Project: Research

  • PMR-116, a Novel Inhibitor of Ribosome Biogenesis with Antitumor Activity in Preclinical Models of Prostate Cancer

    Furic, L. (Primary Chief Investigator (PCI)), Lawrence, M. (Chief Investigator (CI)), Hofman, M. S. (Chief Investigator (CI)), Sandhu, S. (Chief Investigator (CI)), Risbridger, G. (Chief Investigator (CI)), Trigos, A. (Chief Investigator (CI)), Goode, D. (Chief Investigator (CI)), Azad, A. (Chief Investigator (CI)), Haddach, M. (Chief Investigator (CI)) & Hannan, K. M. (Chief Investigator (CI))

    9/01/2231/08/25

    Project: Research

  • ComBATing lethal prostate cancer with combination Bipolar Androgen Therapy

    Lawrence, M. (Primary Chief Investigator (PCI)), Joshua, A. (Chief Investigator (CI)), Ramm, S. (Chief Investigator (CI)), Risbridger, G. (Associate Investigator (AI)), Clark, A. (Associate Investigator (AI)), Goode, D. (Associate Investigator (AI)), Simpson, K. J. (Associate Investigator (AI)), Brennen, W. N. (Associate Investigator (AI)), Corey, E. (Associate Investigator (AI)) & Nelson, P. S. (Associate Investigator (AI))

    1/01/2231/12/24

    Project: Research